Jaguar Health, Inc. last reported quarterly results on Aug 19, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.2 million (-58.9% year over year) and diluted EPS of -$15.70. It usually reports 7–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 7–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 19, 2026
50 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-58.9%
|
-13
-21.2%
|
-15.70
+95.6%
|
|
Apr 7, 2026
7 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
20
+815.6%
|
9
+182.3%
|
-13.60
+97.7%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
|
-11
-13.1%
|
-584.45
-570.9%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
3
|
-10
-26.8%
|
-26.29
-16.8%
|
|
Aug 13, 2024
44 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Aug 14, 2023
45 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
|
May 15, 2023
45 days after quarter end
|
—
ended Mar 31, 2023
|
—
|
—
|
—
|
|
Nov 14, 2022
45 days after quarter end
|
—
ended Sep 30, 2022
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1585608
- Former names
- Jaguar Animal Health, Inc. (until Jul 31, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.